METASTATIC ENDOMETRIAL CARCINOMA
Clinical trials for METASTATIC ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat ovarian and endometrial cancers
Disease control OngoingThis early-stage trial tests a combination of two drugs, APG-1252 and cobimetinib, in people whose ovarian or endometrial cancer has returned. The goal is to find the safest dose and see if the drugs can shrink or stabilize tumors. About 42 adults with advanced or recurrent cance…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:51 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial tests whether adding ceralasertib to the targeted therapy trastuzumab deruxtecan (DS-8201a) is safe and effective for people with advanced solid tumors that have HER2 mutations. About 51 adults with various cancers (breast, stomach, colon, and others) will …
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:44 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combination could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while niv…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 07:38 UTC
-
Engineered virus targets Hard-to-Treat endometrial cancer in early trial
Disease control OngoingThis early-phase trial tests a specially designed virus (VSV-hIFNbeta-NIS) that is meant to infect and kill cancer cells while leaving healthy cells alone. It is given intravenously to people with stage IV or recurrent endometrial cancer. The main goals are to find the safest dos…
Matched conditions: METASTATIC ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:48 UTC